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Abstract
Osteoporosis is a disease of the skeleton that becomes more common with advanced age, especially in postmenopausal women.
Osteoporosis increases the risk of fractures, thereby reducing the quality of life for those who suffer from it. Due to the aging
population, direct costs resulting from osteoporosis are projected to reach upward of $25 billion per year by 2025. The main
pharmaceuticals primarily target osteoclasts. Exercise may be an effective method of preventing osteoporosis, although more
research needs to be done. More research should be conducted to explore potential ways to enhance osteoblastic activity as a
method to treat and/or reverse osteoporosis. This review compares the pros and cons of major methods to treat osteoporosis.
Introduction:
Osteoporosis is a disease of the skeleton that becomes
more common with advanced age, especially in postmenopausal women. The CDC reported based on the
data from the NHANES (National Health and Nutrition
Examination Survey) that 10.2 million adults had osteoporosis and 43.4 million had low bone mass, as of 2010
(Looker, 2015). Osteoporosis leads to an increased risk
of fractures, reducing quality of life for those who suffer
from it. Due to the aging population, direct costs resulting
from osteoporosis are projected to swell upward of $25
billion by the year 2025 (Dempster, 2011).The goal of this
review is to present the causes of osteoporosis, explain
the current treatments, and weigh the pros and cons of
the various therapeutics. Can osteoporosis be prevented,
treated, or perhaps even reversed?
Bones are not inanimate objects that the body produces,
rather bone is living tissue that continually undergoes a
process called remodeling, i.e. the continuous degradation and rebuilding of the bone tissue.
Bones are composed of cells connected through a large
extracellular matrix, which is comprised of 15 percent
water, 20 percent collagen fibers, and 55 percent mineralized salts. The main salt is calcium phosphate, which
combines with calcium hydroxide to form crystals of
hydroxyapatite. These crystals continue to combine with
other mineral salts to form a hardened tissue. This process, referred to as calcification, is initiated by cells called
osteoblasts. Mineral salts crystallize in between and then
around collagen fibers. The mixture of stiff crystalized
minerals and flexible collagen provides bones with both
strength and flexibility. Bone tissue is often compared to
reinforced concrete. Collagen is analogous to flexible
metal rods that provide support for the concrete-like
mineral component (Totora & Derrickson, 2014).
There are many reasons for remodeling. Bones can buffer the amount of calcium in the blood by building more
bone mass to use up excess calcium or degrade existing
bone to release calcium when needed. The proper concentration of calcium must be maintained in the body, as
too much calcium can cause a heart attack while too little can cause breathing to stop. There are two hormones
regulating this process. PTH promotes the degradation
of bone, releasing calcium, while Calcitonin promotes the
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deposition of bone, storing calcium.
Other factors that may affect remodeling and the rate
of bone deposition include the availability of minerals that
make up the bone, especially calcium and phosphorus.
Vitamins, particularly Vitamin A which stimulate osteoblasts (the cells that build new bone), and Vitamin C, used
in collagen production, are needed as well. Thyroid hormones (T3 and T4) from the thyroid gland promote bone
growth by stimulating osteoblasts. In addition, the hormone insulin from the pancreas promotes bone growth
by increasing the synthesis of bone proteins (Totora &
Derrickson, 2014).
Sex hormones, including estrogen and testosterone,
also affect bone growth. They are responsible for increased osteoblast activity, which is why post puberty,
many teenagers experience growth spurts. As the level
of sex hormones diminishes during middle age, especially
estrogen in women after menopause, a decrease in bone
mass occurs because bone resorption by osteoclasts
outpaces bone deposition by osteoblasts. Estrogen can
contribute to bone growth by promoting the death of
osteoclasts. In addition, women who have smaller bones
with less mass than those of men run a high risk of developing osteoporosis (Totora & Derrickson, 2014).
Bone remodeling happens in two stages. First, old bone
tissue is broken down and reabsorbed into the blood via
cells called osteoclasts. Then, bone deposition occurs,
whereby osteoblasts deposit collagen fibers and minerals.
Aside from calcium concentrations, remodeling may also
be triggered by factors such as exercise, sedentary lifestyle, and changes in diet. Remodeling helps to fix injured
bone and strengthen areas of bone subject to high stress.
Newer bone is also more fracture-resistant than older
bone (Totora & Derrickson, 2014). If the rate of degradation is higher than the rate of deposition, loss of bone
mass will occur and result in osteoporosis.
Methods
The Touro library’s database and Google were used to find
peer-reviewed articles and papers. Search terms used included “prevention of osteoporosis”, “treatment of osteoporosis”, “adverse effects of osteoporosis treatments”, etc. The
Principles of Anatomy and Physiology 14th edition was used
as well.
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Discussion
Prevention
Although there are several pharmaceuticals that treat
osteoporosis, treatments regimens are often poorly followed. A study of 178 patients on a course of treatment
for osteoporosis found that 23% of patients did not stick
to the prescribed treatment and dropped out. The study
reported a number of reasons for noncompliance, ranging
from expense, inconvenience of use, and fear of side effects (Segal, Tamir, & al, 2003). A large review of 24 studies on osteoporosis treatments found that “One-third to
half of patients do not take their medication as directed.
Nonadherence occurs shortly after treatment initiation”
(Kothawala, Badamgarav, & al, 2007). As mentioned, bone
is living tissue which respond to stress by strengthening
itself. Therefore, applying stress through weight-bearing
exercises could help to stimulate bone strengthening.
A study showed that postmenopausal women who underwent back-muscle training for two years had a higher
bone density than that of a control group. Interestingly,
the effects were not immediately apparent, and were only
evident when measured 8 years after the exercise regimen stopped. Apparently, exercise has long term, but not
immediate effects (M. Sinaki, 2002). Aside from increased
bone health, the impact of stronger muscles results in
enhanced balance, which contributes to fewer falls and
fractures. Conversely, an experiment was conducted to
determine bone loss due to lack of physical stress. Ninety
healthy men were placed on bed rest for 36 weeks and
urine calcium concentration was measured to determine
bone loss. The study found that urine calcium concentrations became elevated to 100 mg a day, showing demineralization of bone. This elevated excretion of calcium in
urine continued for 36 weeks (Schneider, 1984).
How do bones react to physical stress? Bones react
to physical stress through biochemical reaction resulting from mechanical stimulus. Bones contain cells called
osteocytes, osteoblasts that have matured and reside
within bone. Osteocytes are positioned in a way that
the deformation of bone tissue is amplified by 20-100
times on its cell membrane. The deformation on the cell
membrane signals that the bone is undergoing stress.
This is thought to trigger a host of processes within the
cell, resulting in osteogenesis. The process by which osteocytes signal is extremely complex and still not fully
understood (Gusmão & Belangero, 2015). One way osteocytes can signal is through a chemical known as sclerostin, which promotes bone degradation and is coded
for by the gene SOST. Mice with SOST gene deletion and
humans with mutations on this gene have higher bone
density. Mechanical loading has been reported to reduce

sclerostin expression as well. New research is being conducted for an antibody against sclerostin to treat osteoporosis (Bonewald, 2011).
Treatments
The first line of treatment for osteoporosis is currently
Bisphosphonates (BP), which disrupts osteoclastic activity. Because osteoclast are the cells responsible for bone
degradation, many treatments seek to inhibit osteoclast
activity. Osteoclasts degrade bone by releasing hydrogen
ions, thereby creating a acidic environment. They use a
ruffled border that attaches to the bone’s surface. The
ruffled border has crevices created by its protrusions
which act as containers for the acid secreted by the osteoclast. The acid remains in these crevices, which form
small pockets known as sub-osteoclastic compartments
when sealing onto bone. The acidic environment causes
the mineral component of bone to become more soluble, allowing bone’s minerals to be absorbed by the
osteoclasts.
BP has a strong affinity for calcium ions, which are
found in bone, due to the presence of two phosphate
groups, this results in the rapid localization of BP to bone
material. Experiments using radio labeled BP has shown
that BP are taken up and adsorbed in to bone primarily
(Xiao-Long Xu, 2013).
When osteoclasts attach to bone that contains BP the
acidic environment protonates the BP. Protonated BP has
a lowered affinity for calcium ions, allowing for the release of BP into the sub osteoclastic compartment where
BP is taken up by the osteoclast.
BP disrupts cell functions in the osteoclast, BP have
a similar chemical structure to that of pyrophosphate.
Pyrophosphate is involved in many cell processes in the
osteoclast. Due to its similarity to pyrophosphate, BP is
likely to interfere with any of the processes that involve
pyrophosphate. It is thought that the BP inhibits prenylation of protein to the cell membrane, the lack of these
proteins at the membrane results in loss of the ruffled
border and prevents the osteoclast from being able to
degrade the bone.This is shown as bisphosphonate-treated osteoclasts lack a ruffled border (Russell & Rogers,
1999).
Side Effects of BP
Doctors I have spoken with report that patients reported gastrointestinal (GI) discomfort while taking oral BP,
and an NCBI continuing education paper for doctors
states “ All oral bisphosphonates have correlations with
upper gastrointestinal adverse effects, including gastrointestinal reflux, esophagitis, esophageal/gastric ulcers, and
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gastritis. Gastrointestinal side effects are the most common reason for discontinuation of oral bisphosphonates.”
The article recommends avoiding BP in patient that are
at a higher risk of gastrointestinal distress (Ganesan K,
2021). A study conducted to determine the compliance
of patient to osteoporosis treatment found that the
major reason reported by patients for discontinuation of
alendronate (a BP) was indeed GI side effects. Counter
to this, a study conducted to determine if there is any
correlation between alendronate (a BP) use and GI
problems found no correlation of BP use and GI issues.
The experiment was a randomized, double-blind, placebo-controlled trial with a mean follow-up of 3.8 years.
Women were initially randomized to receive alendronate
sodium, 5 mg/d, or placebo. After 2 years, the alendronate
sodium dose was increased to 10 mg/d.The study did not
find any significant correlation between BP use and GI
problems. “The overall incidence of upper GI tract events
was similar in the alendronate and placebo groups”. The
study goes on to suggest that GI side effects reported
may be due to the higher age of osteoporotic patients
(Bauer DC, 2000). The study that found that noncompliance in BP-taking patients also tracked patient adherence
to Raloxifene (a different class of treatment known as a
SERM), none of the Raloxifene-taking patients attributed
the reason of their discontinuation of treatment due to
gastrointestinal issues (Segal,Tamir, & al, 2003).This would
call into question the suggestion that the gastrointestinal
affects attributed to BP are really age related and not resultant of BP. Both groups were of the same population
yet only the BP-taking group reported gastrointestinal
issues. The study cited as well as other studies I came
across that showed no correlation with oral BP use and
upper GI issues were sponsored by pharmaceutical companies that produce oral BPs. These conflicting reports
of gastrointestinal distress due raise eyebrows as to the
potential biases in studies. Patients given intravenous BP
do not report GI issues and the intravenous BPs need to
be administered far less often. (Papapetrou, 2009) Both
reasons make it more likely that a patient will maintain
their intravenous treatment over an oral one and seem
to make intravenous BP optimal.
Another method of treatment for osteoporosis is
monoclonal antibodies. Osteoclasts originate from macrophages. The macrophage precursor cells have a receptor called RANK which binds to RANK ligand (RANKL)
to differentiate into osteoclastic cells. Antibodies can bind
to a ligand to prevent it from binding to its receptor. The
antibodies bind to RANKL inhibiting their ability to bind
with the RANK receptor on the macrophage precursor cells. As a result of the rate at which osteoclasts
36

differentiate is decreases resulting in less osteoclastic
cells that break up bone. (D. A. Hanley, 2012)
Antibody treatment, which circulate in the blood, can
reach all skeletal sites. However, unlike BP which bind to
bones and can have affects after cessation of treatment,
antibodies lose their affect soon after cessation of treatment. Adverse events are rarely associated with denosumab. (Harshika Awasthi, 2018)
Calcium concentration is regulated by hormones PTH,
and calcitonin. Calcitonin is produced in the thyroid gland
and causes lower serum calcium concentration by acting on the renal tubules, causing them to excrete more
calcium, and on osteoclasts, causing them to contract
(temporarily), reducing their motility and ability to resorb bone. It also causes inhibition of carbonic anhydrase
II, which disrupts the acidic environment that is optimal
for osteoclast activity. Calcitonin also prevents osteoclast
precursors from differentiating into their mature form.The
ultimobranchial gland of salmon produces calcitonin with a
different makeup of amino acids. Salmon calcitonin is a 32
amino acid, alpha-helical polypeptide that differs significantly from human calcitonin along amino acids 10-27. Salmon
calcitonin is more potent then endogenous calcitonin due
its difference in amino acids (Felsenfeld AJ, 2015)
Adverse Side Effects of Calcitonin
Adverse effects of calcitonin can include hypocalcemia, a
dangerous condition. Since the calcitonin used to treat
osteoporosis is sourced from salmon, patients who are
allergic to fish can have an allergic reaction. Ten percent
of patients taking calcitonin experience mild nausea that
subsides as therapy continues. A meta-analysis of 21 randomized, controlled clinical trials with calcitonin-salmon
(nasal spray and investigational oral forms) suggests an
increased risk of malignancies in calcitonin-salmon-treated patients (4.1%) compared to placebo-treated patients
(2.9%). A definitive causal relationship between the calcitonin-salmon use and malignancies cannot be established
from this meta-analysis, the benefits for the individual
patient should be carefully evaluated against all possible
risks. (F. Cosman, 2014)
Further studies point to the questionable efficacy of
calcitonin overall and show a definitive lack of efficacy
in nonvertebrate fractures. This contrasts with both bisphosphonates and denosumab which both demonstrated
a lowered fracture risk in vertebral, hip, and other nonvertebral fractures. (Overman RA, 2013)
Calcitonin has been shown to reduce fracture pain.The
exact mechanism for its analgesic effects, is not known.
There is a hypothesis that calcitonin may act on the
central nervous system, and it has been used with some
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success in patients with migraine pain, phantom limb
pain, malignancy, Paget’s disease, and other pathologies. It,
however, has not been compared directly to NSAIDs in
terms of effectiveness of pain relief. Regardless, Calcitonin
may be helpful for pain in patients that cannot tolerate
NSAIDS. (Linsey A Blau, 2016)
Post-menopausal women have low levels of estrogen,
an essential hormone for bone remodeling. Osteoporosis
is attributed to the diminished estrogen levels of postmenopausal women. Estrogen can inhibit osteoclasts from
forming, cause osteoclastic apoptosis, as well as increase
osteoblasts by inhibiting osteoblastic apoptosis (Sundeep
Khosla, 2012) . An obvious therapeutic approach would
be to provide hormone replacement therapy. However,
hormone therapy is found to increase the risk of breast
cancer (Beral, 2003) , and is therefore not widely used .
Raloxifene, a drug that is an estrogen antagonist and agonist is promising drug, in bone, it behaves as an estrogen
antagonist, increasing bone density, in reproductive and
breast tissue it acts as an estrogen agonist.Thus, raloxifene
both increases bone density and reduces risk of cancer.
Raloxifene has not been shown to reduce non-vertebrate
fractions and more research is necessary to determine
its efficacy in non-vertebrate fractures. A meta-analysis
found that “In comparison to other osteoporosis therapies, raloxifene has a lesser impact on bone mineral
density, a similar effect on the occurrence of vertebral
fractures, but no effect on the frequency of non-vertebral
fractures. Raloxifene can be recommended for the prevention of vertebral fractures in women with osteopenia/
osteoporosis who are not at high risk of non-vertebral
fractures and who do not have a past history of venous
thromboembolism” (Ann Cranney, 2005)

exercise, as there is some evidence that links mechanical stress on bones to lasting improved bone mass., and
stronger muscles can improve balance to further help
reduce the risk of falls and fractures. Further research
should be conducted to determine how it might be possible to enhance bone-building osteoblasts.

Conclusion
The most effective current method of treatment are
bisphosphonates, which accumulate in bone and inhibit
osteoclasts from functioning. However, many patients
suffer gastrointestinal pain as a side effect. For those
patients an antibody (denosumab) that prevent RANKL
from signaling the osteoclastic precursor cells to mature,
has also proven to be relatively effective. Other methods
of treatment such as calcitonin and raloxifene while in
theory look promising, proved to not be very effective
in clinical trials. Calcitonin, while not necessarily very effective at reducing bone loss, may still play an important
role in treating pain, especially in patients where NSAIDS
aren’t well tolerated. More research is needed to determine how effective exercise can be in the prevention of
osteoporosis and what specific exercises, if any, would be
most effective. Regardless, patients should be advised to

Felsenfeld AJ, L. B. (2015). Calcitonin, the forgotten hormone: does it deserve to be forgotten? clinical kidney
journal , 8. Retrieved from https://www.ncbi.nlm.nih.gov/
pmc/articles/PMC4370311/
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